Evinature’s CurQD® Shows Real-World Promise in Crohn’s Disease Treatment

For decades, the Crohn’s disease treatment landscape has been defined by immunosuppressants and biologics. These powerful therapies help patients achieve prolonged remission but often come with high costs, a tendency to lose effectiveness over time, and terrible side effects that many patients say are worse than the disease itself.

As the global community living with inflammatory bowel disease (IBD), an umbrella term that includes Crohn’s and ulcerative colitis, continues to grow, there is rising interest in safe, gut-targeted treatments that can work alongside or reduce reliance on conventional drugs.

Earlier this year, that conversation widened with new data from Evinature, the healthcare company behind the plant-based protocol CurQD®. Real-world findings from the treatment were spotlighted at two of the gastroenterology field’s most influential gatherings: the European Crohn’s and Colitis Organization (ECCO) and Digestive Disease Week (DDW) 2025, before being published in Frontiers in Gastroenterology. It is the first retrospective study to focus solely on Crohn’s patients, offering a rare look at how CurQD® works outside of controlled trials.

Understanding Crohn’s Disease: A Growing Global and National Challenge

Crohn’s disease is a chronic inflammatory bowel condition of the digestive tract, marked by abdominal pain, diarrhea, fatigue, and weight loss. Once considered rare, it has become a significant global health issue.

A 2025 analysis estimated that 7 million people worldwide are living with inflammatory bowel disease (IBD), which includes Crohn’s, with cases steadily rising in both developed and developing regions. In the U.S. and Canada, prevalence is projected to reach nearly 0.6% and 0.9% of the population, respectively, by the end of 2025, totaling more than 2.5 million people.

The pediatric burden is especially concerning. A landmark study found over 100,000 Americans under 20 living with IBD, with Crohn’s disease affecting 71 per 100,000 youth, compared to 44 per 100,00 with ulcerative colitis.

Inside the Study

The retrospective study followed 30 patients with active Crohn’s disease treated with CurQD® between mid-2022 and late-2024. Researchers focused on patients who, despite being on stable conventional therapy, still experienced active disease symptoms and added CurQD® to their regimen.

After 8 to 12 weeks of treatment, the results were encouraging:

• 76% of patients achieved clinical response (meaning they felt and functioned noticeably better).
• 75% showed a significant reduction in fecal calprotectin (FCP), an important marker of gut inflammation.
• 55% reached full biomarker remission, showing both improvement and normalization of inflammation markers.
• 84% of patients who responded continued to do well months later, anywhere from two months up to more than two years after starting CurQD®
• No unexpected safety concerns were reported.

What This Means for the Crohn’s Community

For patients, the study points to a treatment option that is both effective and sustainable. The high response rate suggests CurQD® may offer meaningful relief even for those who have struggled with conventional therapies. The long-term retention is particularly important: most patients who improved were able to keep taking CurQD® and maintain their progress well beyond the initial treatment period.

The results also highlight an urgent need for new therapies. Many Crohn’s patients face “biologic fatigue,” where drugs that once worked stop delivering benefits. CurQD® may give these patients another tool to manage their disease without the same risks or costs of escalating pharmaceutical therapy.

A Balanced Path Forward

As with any retrospective, chart-review study, limitations remain. The patient group was small, and there was no control arm for comparison. Larger, prospective trials will be needed to confirm the findings. Still, in the context of everyday clinical practice, the results are promising and hard to ignore.

This pioneering study positions CurQD® as an add-on therapy to increase the success of standard treatments. It sparks a critical conversation: Is it time to integrate clinically proven nutraceuticals like CurQD® within conventional treatment paradigms? And are they the answer for patients seeking relief who are facing biologic fatigue or limited therapeutic bandwidth?

An Opening Note, Not a Full Score

This study is not intended to position CurQD® as a replacement for conventional treatment. But it does signal the potential for integrating nutraceuticals into standard care for Crohn’s disease. For the millions living with IBD, even incremental progress matters.

For Evianture, the findings mark a turning point of a credible, peer-reviewed study that elevated CurQD® from supplement status to an evidence-backed therapeutic option. For patients, it represents the possibility of safer, more sustainable choices in managing Crohn’s disease.